Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2023 | Study Protocol

The efficacy and safety of Sanqi Qushi Granule in patients with idiopathic membranous nephropathy ——protocol of a multicenter, randomized control trial (SQ-AUTUMN)

Authors: Chuang Li, Wenjun Shan, Xing Liang, Qinghua Zhang, Xindong Qin, Sha Jiang, Xiaofan Hong, Lijuan Wang, Ping Li, Haowen Gu, Yi Wang, Kun Bao

Published in: BMC Complementary Medicine and Therapies | Issue 1/2023

Abstract

Background

Adult nephropathy is mainly caused by idiopathic membranous nephropathy (IMN). In cases of proteinuria, Modified Ponticelli Regimens (MPR) are often successful. However, it can cause adverse side effects. Oral Sanqi Qushi Granule (SQG) with MPR is effective in patients with IMN. However, whether it can improve the remission rate of IMN and shorten the remission time is unknown. In this trial, SQG with MPR on IMN will be evaluated clinically for its efficacy and safety.

Methods

We will randomly assign IMN patients who meet the criteria to receives SQG plus cyclical Cyclophosphamide (CTX)/steroids or with placebo plus cyclical CTX/steroids for 6 months. A 12-month follow-up will be conducted on them. Status of remission will be used to assess treatment efficacy.

Discussion

This study aims to appraise whether treatment with SQG plus cyclical CTX/steroids is superior to placebo plus cyclical CTX/steroids in the remission rate of patients with adult IMN. Adverse events of SQG plus MPR will be also evaluated for further researches about Chinese Medicine and MPR on whether it can improve the remission rate of IMN in half a year and shorten the remission time and relieve adverse effects will also be clarified.

Trial registration

Chinese Clinical Trial Registry ChiCTR2200061953. Registered on 13 July 2022.

Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976–1979 and 1995–1997. Am J Kidney Dis. 1997;30(5):621–31.PubMedCrossRef

Keri KC, Blumenthal S, Kulkarni V, Beck L, Chongkrairatanakul T. Primary membranous nephropathy: comprehensive review and historical perspective. Postgrad Med J. 2019;95(1119):23–31.PubMedCrossRef

Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis. 1995;25(6):862–75.PubMedCrossRef

Zhou FD, Zhao MH, Zou WZ, Liu G, Wang H. The changing spectrum of primary glomerular diseases within 15 years: a survey of 3331 patients in a single Chinese centre. Nephrol Dial Transplant. 2009;24(3):870–6.PubMedCrossRef

Mubarak M. The renal histopathological spectrum of patients with nephrotic syndrome: an analysis of 1523 patients in a single Chinese centre. Nephrol Dial Transplant. 2011;26(10):3419. author reply 3419-3420.PubMedCrossRef

Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med. 2011;364(7):689–90.PubMedCrossRef

van de Logt AE, Fresquet M, Wetzels JF, Brenchley P. The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery. Kidney Int. 2019;96(6):1292–302.PubMedCrossRef

Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983–97.PubMedPubMedCentralCrossRef

Lai WL, Yeh TH, Chen PM, Chan CK, Chiang WC, Chen YM, Wu KD, Tsai TJ. Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment. J Formos Med Assoc. 2015;114(2):102–11.PubMedCrossRef

10.

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. Chapter 7 : Idiopathic membranous nephropathy. Kidney Int Suppl (2011). 2012;2(2):186–197.

11.

van den Brand J, Ruggenenti P, Chianca A, Hofstra JM, Perna A, Ruggiero B, Wetzels JFM, Remuzzi G. Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J Am Soc Nephrol. 2017;28(9):2729–37.PubMedPubMedCentralCrossRef

12.

van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(6):1066–73.PubMedPubMedCentralCrossRef

13.

Feng Z, Liu W, Jiang HX, Dai H, Gao C, Dong Z, Gao Y, Liu F, Zhang Z, Zhao Q, et al. How does herbal medicine treat idiopathic membranous nephropathy? Front Pharmacol. 2020;11:994.PubMedPubMedCentralCrossRef

14.

Feng M, Yuan W, Zhang R, Fu P, Wu T. Chinese herbal medicine Huangqi type formulations for nephrotic syndrome. Cochrane Database Syst Rev. 2013;6(6):Cd006335.

15.

Qizhan L, Liming F, Jing H, Kun B, Fei L, Xiuqing W, Min Z. Effect of Tongmai Oral Liquid on Microinflammatory State of Patients with Maintenance Hemodialysis. Chin J Integr Tradit Western Nephrol. 2010;11(05):437–9.

16.

Qun C, Qiang S, Xiaoyan X, Jianhong S, Lixin W, Huan D. Effects of Tongmai Oral Liquid on Renal Artery Hemodynamics in Patients with Chronic Nephritis. J New Chin Med. 2011;43(03):42–3.

17.

Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.PubMedPubMedCentralCrossRef

18.

Zheng Q, Yang H, Liu W, Sun W, Zhao Q, Zhang X, Jin H, Sun L. Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic review and network meta-analysis. BMJ Open. 2019;9(9):e030919.PubMedPubMedCentralCrossRef

19.

Taoying L, Qianwen X, Jianxiong C, Lingjia Y, Jiamin Y, Li H, Qian L, Xiaobo Y, Zhimin Y, Darong W. Development and preliminary optimization of the dampness syndrome scale of Chinese medicine. J Tradit Chin Med. 2021;62(19):1677–83.

20.

van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF. Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J Am Soc Nephrol. 2014;25(1):150–8.PubMedCrossRef

21.

Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, Sasdelli M, Pasquali S, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998;9(3):444–50.PubMedCrossRef

22.

Scolari F, Delbarba E, Santoro D, Gesualdo L, Pani A, Dallera N, Mani LY, Santostefano M, Feriozzi S, Quaglia M, et al. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: The RI-CYCLO Randomized Trial. J Am Soc Nephrol. 2021;32(4):972–82.PubMedPubMedCentralCrossRef

23.

Fernández-Juárez G, Rojas-Rivera J, Logt AV, Justino J, Sevillano A, Caravaca-Fontán F, Ávila A, Rabasco C, Cabello V, Varela A, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99(4):986–98.PubMedCrossRef

24.

Luzardo L, Ottati G, Cabrera J, Trujillo H, Garau M, González Bedat C, Coitiño R, Aunchayna MH, Santiago J, Baldovinos G, et al. Substitution of oral for intravenous cyclophosphamide in membranous nephropathy. Kidney360. 2020;1(9):943–9.PubMedPubMedCentralCrossRef

25.

Mao W, Zhang L, Zou C, Li C, Wu Y, Su G, Guo X, Wu Y, Lu F, Lin Q, et al. Rationale and design of the Helping Ease Renal failure with Bupi Yishen compared with the Angiotensin II Antagonist Losartan (HERBAAL) trial: a randomized controlled trial in non-diabetes stage 4 chronic kidney disease. BMC Complement Altern Med. 2015;15:316.PubMedPubMedCentralCrossRef

26.

Mao W, Yang N, Zhang L, Li C, Wu Y, Ouyang W, Xu P, Zou C, Pei C, Shi W, et al. Bupi Yishen formula versus losartan for non-diabetic stage 4 chronic kidney disease: a randomized controlled trial. Front Pharmacol. 2020;11:627185.PubMedCrossRef

27.

Xie J, Chen N. Primary glomerulonephritis in mainland China: an overview. Contrib Nephrol. 2013;181:1–11.PubMedCrossRef

28.

Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825–30.PubMedCrossRef

29.

Chen S, Ren S, Wang AY, Tran H, Li Z, Cheng X, Liu M, Li G, Wang L, Hong D. Comparison of the efficacy and safety of tacrolimus monotherapy and cyclophosphamide combined with glucocorticoid in the treatment of adult primary membranous nephropathy: protocol of a multicenter, randomized, controlled, open study. Trials. 2020;21(1):219.PubMedPubMedCentralCrossRef

30.

Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener’s granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998;9(5):842–52.PubMedCrossRef

31.

Knight A, Askling J, Granath F, Sparen P, Ekbom A. Urinary bladder cancer in Wegener’s granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis. 2004;63(10):1307–11.PubMedPubMedCentralCrossRef

32.

Xu J, Hu X, Xie J, Chen N. Management of Membranous Nephropathy in Asia. Kidney Dis (Basel). 2015;1(2):119–25.PubMedCrossRef

33.

Lu Z, Liu W, Gao H, Chen W, Ge W, Li F, Deng Y. Traditional Chinese Medicine as an adjunct therapy in the treatment of idiopathic membranous nephropathy: a systematic review and meta-analysis. PLoS One. 2021;16(5):e0251131.PubMedPubMedCentralCrossRef

34.

Zhai R, Jian G, Chen T, Xie L, Xue R, Gao C, Wang N, Xu Y, Gui D. Astragalus membranaceus and Panax notoginseng, the Novel Renoprotective Compound, Synergistically Protect against Podocyte Injury in Streptozotocin-Induced Diabetic Rats. J Diabetes Res. 2019;2019:1602892.PubMedPubMedCentralCrossRef

35.

Han H, Cao A, Wang L, Guo H, Zang Y, Li Z, Zhang X, Peng W. Huangqi Decoction Ameliorates Streptozotocin-Induced Rat Diabetic Nephropathy through Antioxidant and Regulation of the TGF-β/MAPK/PPAR-γ Signaling. Cell Physiol Biochem. 2017;42(5):1934–44.PubMedCrossRef

36.

Tang X, Huang M, Jiang J, Liang X, Li X, Meng R, Chen L, Li Y. Panax notoginseng preparations as adjuvant therapy for diabetic kidney disease: a systematic review and meta-analysis. Pharm Biol. 2020;58(1):138–45.PubMedPubMedCentralCrossRef

37.

Liu C, Kang Y, Zhou X, Yang Z, Gu J, Han C. Rhizoma smilacis glabrae protects rats with gentamicin-induced kidney injury from oxidative stress-induced apoptosis by inhibiting caspase-3 activation. J Ethnopharmacol. 2017;198:122–30.PubMedCrossRef

38.

Guo Y, Xiao Y, Zhu H, Guo H, Zhou Y, Shentu Y, Zheng C, Chen C, Bai Y. Inhibition of proliferation-linked signaling cascades with atractylenolide I reduces myofibroblastic phenotype and renal fibrosis. Biochem Pharmacol. 2021;183:114344.PubMedCrossRef

39.

Liu R, Pei Q, Shou T, Zhang W, Hu J, Li W. Apoptotic effect of green synthesized gold nanoparticles from Curcuma wenyujin extract against human renal cell carcinoma A498 cells. Int J Nanomedicine. 2019;14:4091–103.PubMedPubMedCentralCrossRef

40.

Li X, Wang Y, Wang K, Wu Y. Renal protective effect of Paeoniflorin by inhibition of JAK2/STAT3 signaling pathway in diabetic mice. Biosci Trends. 2018;12(2):168–76.PubMedCrossRef

41.

Tian R, Wang L, Chen A, Huang L, Liang X, Wang R, Mao W, Xu P, Bao K. Sanqi oral solution ameliorates renal damage and restores podocyte injury in experimental membranous nephropathy via suppression of NFκB. Biomed Pharmacother. 2019;115:108904.PubMedCrossRef

42.

Wang X, Liu J, Tian R, Zheng B, Li C, Huang L, Lu Z, Zhang J, Mao W, Liu B, et al. Sanqi Oral Solution Mitigates Proteinuria in Rat Passive Heymann Nephritis and Blocks Podocyte Apoptosis via Nrf2/HO-1 Pathway. Front Pharmacol. 2021;12:727874.PubMedPubMedCentralCrossRef

43.

Tian R, Wang P, Huang L, Li C, Lu Z, Lu Z, Wu A, Bao K, Mao W, Huang Q, et al. Sanqi Oral Solution Ameliorates Renal Ischemia/Reperfusion Injury via Reducing Apoptosis and Enhancing Autophagy: Involvement of ERK/mTOR Pathways. Front Pharmacol. 2020;11:537147.PubMedPubMedCentralCrossRef

Title: The efficacy and safety of Sanqi Qushi Granule in patients with idiopathic membranous nephropathy ——protocol of a multicenter, randomized control trial (SQ-AUTUMN)
Authors: Chuang Li
Wenjun Shan
Xing Liang
Qinghua Zhang
Xindong Qin
Sha Jiang
Xiaofan Hong
Lijuan Wang
Ping Li
Haowen Gu
Yi Wang
Kun Bao
Publication date: 01-12-2023
Publisher: BioMed Central
Published in: BMC Complementary Medicine and Therapies / Issue 1/2023
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-023-03950-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The efficacy and safety of Sanqi Qushi Granule in patients with idiopathic membranous nephropathy ——protocol of a multicenter, randomized control trial (SQ-AUTUMN)

Abstract

Background

Methods

Discussion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Discussion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2023

Exploring the safety and efficacy of phytomedicine Petiveria alliacea extract (Esperanza) in patients with metastatic gastrointestinal tumors and acute leukemias: study protocol for a phase Ib/randomized double blind phase II trial (PA001)

Forsythiaside A ameliorates sepsis-induced acute kidney injury via anti-inflammation and antiapoptotic effects by regulating endoplasmic reticulum stress

Protocatechuic aldehyde acts synergistically with dacarbazine to augment DNA double-strand breaks and promote apoptosis in cutaneous melanoma cells

Danlou Recipe promotes cholesterol efflux in macrophages RAW264.7 and reverses cholesterol transport in mice with hyperlipidemia induced by P407

Gut microbiota mediated the therapeutic efficiency of Simiao decoction in the treatment of gout arthritis mice

Honey proteins regulate oxidative stress, inflammation and ameliorates hyperglycemia in streptozotocin induced diabetic rats